ADA 308 - Aranda Pharma
Alternative Names: ADA308Latest Information Update: 07 Oct 2024
At a glance
- Originator Aranda Pharma
- Class Antianaemics; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acne; Alopecia
- Discontinued Prostate cancer
Most Recent Events
- 01 Aug 2024 Pharmacokinetics and pharmacodynamics data from a preclinical study in prostate cancer released by Aranda Pharma
- 20 Jul 2023 Discontinued - Preclinical for Prostate cancer in Finland (Aranda Pharma pipeline, July 2023)
- 20 Jul 2023 Preclinical trials in Acne in Finland (Topical) (Aranda Pharma pipeline, July 2023)